News

  • FDA Awards Precision Antibody Contract to Develop Monoclonal Antibodies for Influenza Vaccine Potency Assays

    COLUMBIA, Md., October 20, 2011—Precision Antibody™ announced today its selection by the United States Food and Drug Administration (FDA) to develop monoclonal antibodies to influenza virus antigens for both Influenza A and B. These antibodies will be used for in vitro assays to develop new vaccine potency assays. The term of the monoclonal development and antibody production contract is for one year with the option of five additional years.

  • EPA Awards Precision Antibody Contract to Develop Monoclonal Antibodies for Detection of Parasites in Water Resources

    COLUMBIA, Md., August 23, 2010—Precision Antibody™announced today its selection by the United States Environmental Protection Agency (EPA) to develop monoclonal antibodies to two species of Cryptosporidium (“Crypto”), an intestinal parasite that has emerged over the past 20 years as one of the most common causes of waterborne illness in the United States. According to the U.S. Centers for Disease Control and Prevention, between 2006–2008, Crypto was responsible for 42 percent of reported recreational water-associated gastroenteritis in the United States, and six percent of reported drinking water-associated outbreaks. The development of antibodies that substantially improve the sensitivity and specific detection and typing of this parasite over currently available methods may lead to improved tests for detecting Crypto in drinking water supplies and recreational waters as well as the potential to develop effective treatments for people infected by the pathogen.

  • Precision Antibody Selected to Provide Antibody Characterization for National Cancer Institute’s Clinical Proteomics Technologies for Cancer (CPTC) Initiative

    COLUMBIA, Md., July 21, 2010—Precision Antibody™ announced today its selection by Science Applications International Corporation–Frederick (SAIC-F) to provide antibody and antigen characterization, including surface plasmon resonance (SPR) analysis, for the National Cancer Institute’s “Clinical Proteomic Technologies for Cancer” (CPTC) initiative (www.proteomics.cancer.gov). A goal of the CPTC is to develop a standardized resource of very high-quality, renewable reference antibodies generated against cancer-related proteins. The antibodies will be made available to proteomics researchers, along with characterization data and other information intended to support replication and standardization.

  • Precision Antibody to Develop Antibodies for NCI's Proteomic's Initiative

    COLUMBIA, Md., October 27, 2009—Precision Antibody™ has been selected as the antibody developer for a component of the National Cancer Institute (NCI)’s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research. The contract award is the result of a third solicitation for contract proposals from custom antibody suppliers as part of the Clinical Proteomic Reagents Resources component of the CPTC, whose mission is to develop high-quality, standardized, renewable reagents that are needed for effective proteomic analysis.